Think this one could have the potetial to be really big... Check out the company info and post any thoughts you have... has massive potential

Widow and Orphan status springs to mind! - no not the patients who are delayed treatment by the FDA ( see RNS and sp fall today - Yikes!),
No, - I mean the remaining family who "might" have been spared widowhood, at least for a few more weeks, months, etc.

Of course FDA has a responsibility towards trial patients - but to delay Trials twice smacks of Nimbyism, but that's just a sly view - if they fall any further, I might buy for the "future" - the present can't get much worse - or can it?

Perhaps we should allow more foreigners into Britain provided they take part in Trials - they wouldn't mind, would they?

Attention, Attention....

These boys are shifting, look out

Nice rise yesterday, how far is it likely to go. Current sp of 13.75 mid is mcap of 21million approx. Was 12million 2 days ago.

yeah, I have my stop loss set at 13p at the moment..... I think they could be good to 15p maybe, but time will tell.

The Government had passed a new bill unrestricting the use of certain stem cell techniques

Very surprised that this has not been flagged up in the last few days.
Share price rise has been terrific on the news from America that the FDA has authorised stem cell research to go ahead in human tests, and it has also been ok`d by UK authorities to go ahead with their stroke stem cells in human tests.
They are still talking to the FDA, and if this turns positive then the price at the moment will be extremely cheap.

Alert serviceSite mapSearchHome
Home News & events NewsNews article
ReNeuron gains UK regulatory approval to start ground-breaking clinical trial with stem cell therapy for stroke . 19/01/09
Guildford, UK, 19 January 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a first-in-man clinical trial for the treatment of patients who have been left disabled by an ischaemic stroke, the most common form of the condition. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world.

In this ground-breaking Phase I trial, the first of its kind using expanded neural stem cells, stroke patients will be treated with ReNeuron's ReN001 stem cell therapy at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board. The Principal Investigator for the trial is Dr. Keith Muir, Senior Lecturer in Neurology at the University of Glasgow. MHRA approval for the trial has been given subject to provision of data both from an ongoing pre-clinical study and from the long term follow-up of trial participants. Following successful completion of the ethics approval process which is currently underway for the trial, patient recruitment is expected to commence in the second quarter of this year.

The trial is designed primarily to test the safety profile of ReN001 in ischaemic stroke patients at a range of cell doses, but a number of efficacy measures will also be evaluated over the course of the trial. The ReN001 cells will be administered by direct injection into the affected region of the brain in a straightforward surgical procedure. Importantly, the nature of the procedure and the characteristics of the ReN001 cells mean that the patients will not require immunosuppression following treatment, thus eliminating the safety risks typically associated with immunosuppression regimens. Patients in the trial will be monitored for one year, with longer term follow-up procedures in place thereafter.

Dr. Keith Muir said:

"Stem cell treatment offers the potential to repair brain tissue lost as a result of stroke. We are very excited at the opportunity to undertake this, the first clinical trial involving neural stem cell therapy in stroke. At this stage, we are primarily seeking to establish the safety and feasibility of this form of treatment, and if successful, we hope that it will lead on to larger studies looking at the effects of the treatment on patient recovery".


Michael Hunt, Chief Executive Officer of ReNeuron, said:

"This regulatory approval marks the first step in the process of testing the safety and potency of our lead ReN001 stroke therapy at a clinical level. It is the most important milestone in ReNeuron's history thus far and also represents a significant development in the wider field as regards the translation of exciting stem cell science into clinical stage therapies. In many ways, ReNeuron has set the regulatory pathway in the UK for cell therapy trials of this type, and we are delighted to have been given the opportunity to move ReN001 into its clinical phase on home territory in the UK"


Enquiries:

ReNeuron

IMHO, A lot of hot air, for this Co has had a far greater Punter Interest ( and sp) quite some while ago. In that event they muffed it, destroying many shareholder beliefs that this was the way forward.
So not everyone believes this is the start of something BIG....rather it's the same old hooey, relaunched in another guise.
Today, the sp shows that 4x as many punters want "out" as are willing to pay "spike prices" - - - Oh deary.

New article, Click HERE

FUND-Raising at 3p/Share

Oh deary, for retail shareholders - this will mean DILUTION, no wonder the sp has fallen so quickly today!

-and the way I read it most of this 3million is already spoken-for by way of repaying Loans . . . . . can someone else explain otherwise?

No need to explain hangon - you're a PI, and you've been shafted

Don't worry though - no need to lose any sleep as the institutions and the board have all been looked after.

This is a dummy company...bail out and don't invest in it.

Couldn't agree more - the board, its advisors et al are init for themselves, and themselves only.

What posters on other boards are assuming is that this fund raising will be enough - that in itself is highly debatable, but the board has certainly shown how it would like to spread the rewards if and when they do come - certainly ain't gonna be for the PI

Maybe one to tuck away in the bottom draw with this news, if the research comes good could be worth a bit.,.

Thursday we'll have annual results from ReNeuron , the stem technology researcher. The firm is not in profit yet, but it has high hopes for its ReN001 stem cell therapy for the treatment of the effects of a stroke. It is currently in clinical development.

Stroke Trial Update
RNS
RNS Number : 9276J
ReNeuron Group plc
14 August 2012










14 August 2012
AIM: RENE



ReNeuron Group plc

("ReNeuron" or the "Company")



ReNeuron receives DSMB clearance to progress to higher dose in stem cell clinical trial in stroke patients



First patient treated in this higher dose cohort



Guildford, UK, 14 August 2012: ReNeuron Group plc (AIM: RENE) today provides an update on progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. In this open label, dose-ranging Phase I safety study, taking place in Scotland, ReNeuron's ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.



The Company is pleased to report that the independent Data Safety Monitoring Board (DSMB) for the clinical trial has recommended that the trial advances to the evaluation of a higher dose of ReN001 in the third of four dose cohorts to be treated in the study. In arriving at this recommendation, the DSMB reviewed safety data from the first two dose cohorts of six patients treated with ReN001. Of these patients, two are through 18 month follow-up, one is through 12 month follow-up, one is through 9 month follow-up, one is through 6 month follow-up and one is through three month follow-up. No cell-related adverse events or adverse immune-related responses have been reported in any of the patients treated to date.



The Company is also pleased to report that the first patient in this third dose cohort of three patients has now been successfully treated with ReN001 and discharged from hospital with no acute safety issues arising.



The primary aim of the PISCES study is to test the safety and tolerability of the treatment in ascending doses of the ReN001 cells, in patients with moderate to severe functional neurological impairments resulting from their stroke. The secondary aim of the study is to evaluate efficacy measures for the design of future clinical trials with ReN001, including imaging measures as well as a number of tests of sensory, motor and cognitive functions.



In June of this year, interim data from the PISCES study from the first five patients treated was presented by the Glasgow clinical team at Glasgow at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Yokohama, Japan. Reductions in neurological impairment and spasticity were observed in all five patients compared with their stable pre-treatment baseline performance and these improvements were sustained in longer term follow-up.



The PISCES study is the world's first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world. The trial is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.



As announced recently, the Company expects that, subject to a continuing lack of cell-related adverse events and affirmative Data Safety Monitoring Board advice, the remaining patients in the PISCES study will have been recruited and treated by early 2013, leaving the Company on track to submit an application for a Phase II clinical study with ReN001 by mid-2013. These remaining patients have already been identified and evaluated as potentially eligible for treatment in the PISCES study, subject to further screening and consenting visits.



Michael Hunt, Chief Executive Officer of ReNeuron, said:



"We are delighted that the DSMB have given a favourable recommendation to proceed to the higher and penultimate dose in the PISCES stroke trial. This represents a further important milestone for the study as we make our plans for a subsequent Phase II clinical trial application with ReNeuron's ReN001 cell-based treatment for stroke disability."

Spot the movers 3.10 / 3.20p not any longer

After plenty of 50K sells at offer 3.20p ( order book ) the last one of 750K got the shares moving

15 small-cap stocks to buy now
By MoneyWeek Editor John Stepek / Sep 27, 2012

Tom: I’ll stick with the biotech theme. One of the few British players is ReNeuron (LSE: RENE), which basically drills holes into the heads of people who have had a stroke, and injects stem cells to try to revive the part of the brain that has been damaged. It’s early days, but so far the treatment doesn’t seem to do these people any harm and there is early evidence that it does some good.

The interesting thing is that Reneuron’s experience is consistent with what has been reported from stem cell trials elsewhere, notably in America. Stem cell medicine is definitely something to keep an eye on, and is part of the emerging business of regenerative medicine.

http://www.moneyweek.com/investment-advice/share-tips/roundtable-15-small-cap-stocks-that-will-grow-through-recession-60824

Have made several buys recently; latest today. Still not being reflected on trade either by correct quantity or type of transaction.

Looks like MM are using 'automatic stabilizer' trades to hold SP at their desired level. Lots of interest in Stem-cell research and relatively few stockmarket companies trading in such technology.

Recent Cell transplant on spinal nerve has just enabled a paralised man to walk again. This is a massive step in tissue repair and Cell regeneration.

DYOR

HAb

I think this may be worth watching or holding for the long term.
Neil Woodford recently bought more and now holds about
20%. News.